E
Eupraxia Pharmaceuticals Inc. (EPRX)
NCM – Real vaqt narxi. Valyuta: USD
7.61
+0.19 (2.56%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
7.61
+0.19 (2.56%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Eupraxia Pharmaceuticals Inc., klinik bosqichdagi biotexnologiya kompaniyasi, tibbiy ehtiyojlari qondirilmagan terapevtik sohalarni davolash uchun mahsulotlarni ishlab chiqishga qaratilgan. Uning patentlangan Diffusphere texnologiyasi tibbiy ehtiyojlari sezilarli darajada qondirilmagan qo'llanmalar uchun dori etkazib berishni optimallashtiradi. Kompaniyaning mahsulot portfeliga EP-104IAR, tizza osteoartritini davolash uchun III bosqich klinik sinovlarida; EP-104GI, eosinofilik ezofagitni davolash uchun II bosqich klinik sinovlarida; va EP-104, oshqozon-ichak trakti, masalan, eosinofilik ezofagitni davolash uchun preklinik tadqiqotlar ostida. Kompaniya ilgari Plaza Capital Partners Inc. nomi bilan tanilgan va 2012 yil may oyida Eupraxia Pharmaceuticals Inc. nomini o'zgartirgan. Eupraxia Pharmaceuticals Inc. 2011 yilda ro'yxatga olingan va uning shtab-kvartirasi Kanadaning Viktoriya shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer & COO |
| Dr. James A. Helliwell FRCPC, M.D. | CEO & Director |
| Mr. Alex Therien | Executive VP of R&D |
| Mr. Alexander John Rothwell Eng., M.B.A. | Chief Financial Officer |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Corporate Development Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 6-K | f6k_050626.htm |
| 2026-05-05 | 6-K | f6k_050526.htm |
| 2026-05-01 | 6-K | f6k_050126.htm |
| 2026-04-22 | 6-K | f6k_042126.htm |
| 2026-04-21 | 6-K | f6k_042126.htm |
| 2026-04-15 | 6-K | f6k_041426.htm |
| 2026-03-17 | 6-K | f6k_031726.htm |
| 2026-03-13 | 40-F | d78249d40f.htm |
| 2026-02-20 | SUPPL | d100065dsuppl.htm |
| 2026-02-20 | 6-K | d219539d6k.htm |